128 related articles for article (PubMed ID: 31569999)
1. Gα
Yagi H; Onoyama I; Asanoma K; Hori E; Yasunaga M; Kodama K; Kijima M; Ohgami T; Kaneki E; Okugawa K; Yahata H; Kato K
FASEB J; 2019 Dec; 33(12):13683-13694. PubMed ID: 31569999
[TBL] [Abstract][Full Text] [Related]
2. GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer.
Yagi H; Asanoma K; Ohgami T; Ichinoe A; Sonoda K; Kato K
Oncogene; 2016 Aug; 35(34):4471-80. PubMed ID: 26804165
[TBL] [Abstract][Full Text] [Related]
3. Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability [corrected].
Ho KC; Zhou Z; She YM; Chun A; Cyr TD; Yang X
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4870-5. PubMed ID: 21383157
[TBL] [Abstract][Full Text] [Related]
4. Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity.
Salah Z; Melino G; Aqeilan RI
Cancer Res; 2011 Mar; 71(5):2010-20. PubMed ID: 21212414
[TBL] [Abstract][Full Text] [Related]
5. Naturally occurring hotspot cancer mutations in Gα
Maziarz M; Federico A; Zhao J; Dujmusic L; Zhao Z; Monti S; Varelas X; Garcia-Marcos M
J Biol Chem; 2020 Dec; 295(49):16897-16904. PubMed ID: 33109615
[TBL] [Abstract][Full Text] [Related]
6. Role of Galpha12 and Galpha13 as novel switches for the activity of Nrf2, a key antioxidative transcription factor.
Cho MK; Kim WD; Ki SH; Hwang JI; Choi S; Lee CH; Kim SG
Mol Cell Biol; 2007 Sep; 27(17):6195-208. PubMed ID: 17591699
[TBL] [Abstract][Full Text] [Related]
7. The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway.
Salah Z; Itzhaki E; Aqeilan RI
Oncotarget; 2014 Nov; 5(21):10886-900. PubMed ID: 25350971
[TBL] [Abstract][Full Text] [Related]
8. Regulation of apoptosis by alpha-subunits of G12 and G13 proteins via apoptosis signal-regulating kinase-1.
Berestetskaya YV; Faure MP; Ichijo H; Voyno-Yasenetskaya TA
J Biol Chem; 1998 Oct; 273(43):27816-23. PubMed ID: 9774391
[TBL] [Abstract][Full Text] [Related]
9. Divergent C-terminal motifs in Gα12 and Gα13 provide distinct mechanisms of effector binding and SRF activation.
Stecky RC; Quick CR; Fleming TL; Mull ML; Vinson VK; Whitley MS; Dover EN; Meigs TE
Cell Signal; 2020 Aug; 72():109653. PubMed ID: 32330601
[TBL] [Abstract][Full Text] [Related]
10. WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells.
Yeung B; Ho KC; Yang X
PLoS One; 2013; 8(4):e61027. PubMed ID: 23573293
[TBL] [Abstract][Full Text] [Related]
11. Gα12 structural determinants of Hsp90 interaction are necessary for serum response element-mediated transcriptional activation.
Montgomery ER; Temple BR; Peters KA; Tolbert CE; Booker BK; Martin JW; Hamilton TP; Tagliatela AC; Smolski WC; Rogers SL; Jones AM; Meigs TE
Mol Pharmacol; 2014 Apr; 85(4):586-97. PubMed ID: 24435554
[TBL] [Abstract][Full Text] [Related]
12. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
[TBL] [Abstract][Full Text] [Related]
13. Different Raf protein kinases mediate different signaling pathways to stimulate E3 ligase RFFL gene expression in cell migration regulation.
Gan X; Wang C; Patel M; Kreutz B; Zhou M; Kozasa T; Wu D
J Biol Chem; 2013 Nov; 288(47):33978-33984. PubMed ID: 24114843
[TBL] [Abstract][Full Text] [Related]
14. NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation.
Salah Z; Cohen S; Itzhaki E; Aqeilan RI
Cell Cycle; 2013 Dec; 12(24):3817-23. PubMed ID: 24107629
[TBL] [Abstract][Full Text] [Related]
15. Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells.
O'Hayre M; Inoue A; Kufareva I; Wang Z; Mikelis CM; Drummond RA; Avino S; Finkel K; Kalim KW; DiPasquale G; Guo F; Aoki J; Zheng Y; Lionakis MS; Molinolo AA; Gutkind JS
Oncogene; 2016 Jul; 35(29):3771-80. PubMed ID: 26616858
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.
Ping H; Guo L; Xi J; Wang D
Tumour Biol; 2017 Jun; 39(6):1010428317713389. PubMed ID: 28651497
[TBL] [Abstract][Full Text] [Related]
17. Receptor selectivity between the G proteins Gα
Mackenzie AE; Quon T; Lin LC; Hauser AS; Jenkins L; Inoue A; Tobin AB; Gloriam DE; Hudson BD; Milligan G
FASEB J; 2019 Apr; 33(4):5005-5017. PubMed ID: 30601679
[TBL] [Abstract][Full Text] [Related]
18. A Blk-p190RhoGAP signaling module downstream of activated Gα13 functionally opposes CXCL12-stimulated RhoA activation and cell invasion.
Bartolomé RA; Díaz-Martínez M; Coló GP; Arellano-Sánchez N; Torres-Ayuso P; Kleinovink JW; Mérida I; Teixidó J
Cell Signal; 2014 Nov; 26(11):2551-61. PubMed ID: 25025568
[TBL] [Abstract][Full Text] [Related]
19. LATS1/2 control TGFB-directed epithelial-to-mesenchymal transition in the murine dorsal cranial neuroepithelium through YAP regulation.
Martínez Traverso IM; Steimle JD; Zhao X; Wang J; Martin JF
Development; 2022 Sep; 149(18):. PubMed ID: 36125128
[TBL] [Abstract][Full Text] [Related]
20. SUMOylation of large tumor suppressor 1 at Lys751 attenuates its kinase activity and tumor-suppressor functions.
Mei L; Yuan L; Shi W; Fan S; Tang C; Fan X; Yang W; Qian Y; Hussain M; Wu X
Cancer Lett; 2017 Feb; 386():1-11. PubMed ID: 27847303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
